IPO activity continued at a record pace this past week with 19 IPOs, marking the fourth week in 2021 with at least 17 US IPOs, the most since the year 2000. With the August lull around the corner, the pipeline saw less activity than usual; five IPOs and 13 SPACs...read more
Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, raised $304 million by offering 19 million shares at $16, the high end of the range of $14 to $16. The company offered 2 million more shares than anticipated. It...read more
Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, raised the proposed deal size for its upcoming IPO on Thursday. The Berkeley, CA-based company now plans to raise $255 million by offering 17 million shares at a...read more
Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, announced terms for its IPO on Monday. The Berkeley, CA-based company plans to raise $203 million by offering 13.5 million shares at a price range of $14 to...read more
US IPO Weekly Recap: Life sciences, software, and more ride the summer wave in a 19 IPO week
IPO activity continued at a record pace this past week with 19 IPOs, marking the fourth week in 2021 with at least 17 US IPOs, the most since the year 2000. With the August lull around the corner, the pipeline saw less activity than usual; five IPOs and 13 SPACs...read more
Gene editing biotech Caribou Biosciences prices further upsized IPO at $16 high end
Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, raised $304 million by offering 19 million shares at $16, the high end of the range of $14 to $16. The company offered 2 million more shares than anticipated. It...read more
Gene editing biotech Caribou Biosciences ups share offering by 26% ahead of $255 million IPO
Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, raised the proposed deal size for its upcoming IPO on Thursday. The Berkeley, CA-based company now plans to raise $255 million by offering 17 million shares at a...read more
Gene editing biotech Caribou Biosciences sets terms for $203 million IPO
Caribou Biosciences, a Phase 1 biotech developing gene edited cell therapies for multiple cancers, announced terms for its IPO on Monday. The Berkeley, CA-based company plans to raise $203 million by offering 13.5 million shares at a price range of $14 to...read more